| First Author | Riker DK | Year | 1981 |
| Journal | J Neurochem | Volume | 37 |
| Issue | 3 | Pages | 649-54 |
| PubMed ID | 6115889 | Mgi Jnum | J:6585 |
| Mgi Id | MGI:55060 | Doi | 10.1111/j.1471-4159.1982.tb12536.x |
| Citation | Riker DK, et al. (1981) Increased noradrenergic metabolism in the cerebellum of the mouse mutant dystonia musculorum. J Neurochem 37(3):649-54 |
| abstractText | The neurological mouse mutant dystonia musculorum exhibits bizarre appendicular and truncal dystonia without known cerebellar histopathology. We evaluated striatal dopamine and cerebellar norepinephrine metabolism in this mutant and compared the results with those obtained in wild-type BALB/c and B6C3 controls. Tyrosine hydroxylase activity and dopamine metabolite levels (homovanillic acid and 3,4-dihydroxyphenylacetic acid) in the striatum of the mutant were similar to controls. Tyrosine hydroxylase activity and the steady-state level of 3-methoxy-4-hydroxyphenethyleneglycol, a metabolite of norepinephrine, in the cerebellum were 38% and 42-66%, respectively, greater in the mutant. However, the level of norepinephrine was similar (approximately 350 ng/g). Further, a Purkinje cell-specific marker, cGMP-dependent protein kinase, was unchanged in the mutant and no Purkinje cell pathology was observed with light microscopy. The lack of Purkinje cell derangement and similar levels of cerebellar norepinephrine and cGMP-dependent protein kinase activity suggest that increased norepinephrine metabolism in the cerebellum of this mutant is not a morphological response to gross target cell loss during morphogenesis. The observed changes may be a reaction to abnormal impulse traffic or altered input/output pathways to the mutant cerebellum during its development. |
